Navigation Links
Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development
Date:5/27/2009

-grade dysplasia or high-grade dysplasia, and then finally cancer. The present study included patients with the later stages of low- and high-grade dysplasia.

Beginning in 2006, the AIM Dysplasia Trial enrolled 127 patients having a diagnosis of Barrett's esophagus with dysplasia, the most advanced stage of this condition. Patients were randomly assigned to receive either endoscopic ablation with the HALO system or a sham intervention (control, no treatment). Tissue samples (biopsies) were obtained from the esophagus at regular intervals for one year after enrollment to assess for the presence of early Barrett's, dysplasia, and esophageal cancer. Comparison of the biopsy results at one year served as the primary outcome for the trial. The study endpoints were the eradication of all early Barrett's and, separately, all dysplasia in each group, as well as occurrence of new esophageal cancers.

At one-year follow-up, patients treated with ablation had a significantly higher complete eradication rate for both early Barrett's and dysplasia as compared to the control group. More than three quarters of treated patients had no detectable Barrett's at the end of the treatment period, compared to sham patients where 98% had persistent disease. The overall rate of disease progression to more severe forms of dysplasia and cancer was significantly lower in the ablation treatment group (3.6%) as compared to the control group (16.3%). In the highest risk cohort (high-grade dysplasia), ablative therapy significantly reduced the risk of progression to cancer by nearly 90% compared to control (2.4% in treated patients versus 19.0% in untreated controls).

About BARRX Medical, Inc.

BARRX Medical, Inc. develops treatment solutions for Barrett's esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its main product, the HALO
'/>"/>

SOURCE BARRX Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
2. New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
3. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
4. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
5. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
6. Study Confirms Effectiveness of Innovative Prism Glasses For Hemianopia Patients
7. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
10. VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
11. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... IRIDEX Corporation (Nasdaq: IRIX ) today ... ended June 28, 2014.  , Revenues were $10.6 ... $9.2 million in the 2013 second quarter and up sequentially ... for the first six months of 2014 were $20.9 million, ... of last year. , Gross margin for the quarter ...
(Date:7/31/2014)... Diabetes Care®, Inc. (NASDAQ: TNDM ), a medical ... reported its financial results for the quarter ended June 30, ... 2014 to the same period of 2013: , Sales ... , t:slim Pump shipments grew 64 percent to 2,235 pumps ... June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... Inc. (the "Company") (Nasdaq: PCYC ) today reported ... 30, 2014. Financial Results for the Six Months ... for the quarter ended June 30, 2014 increased to $113.0 ... 2013 primarily due to IMBRUVICA ® (ibrutinib) net product ... the six months ended June 30, 2014 increased to $232.4 ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25
... SAN FRANCISCO , June 22 Jennerex, Inc., ... Gregory W. Schafer as senior vice president and chief financial ... planning, investor relations and treasury functions. , ... "Greg,s finance and operations experience in the ...
... BENTONVILLE, Ark. , June 22 Walmart (NYSE: ... today they,re teaming up to provide an affordable insulin option for people with ... Beginning in mid-September, Lilly,s ... pharmacies across the U.S. under the dual-branded name Humulin ® ReliOn ...
Cached Medicine Technology:Jennerex Appoints Gregory W. Schafer as Chief Financial Officer 2Jennerex Appoints Gregory W. Schafer as Chief Financial Officer 3Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 2Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 3Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 4Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 5
(Date:8/1/2014)... Lake City, UT (PRWEB) August 01, 2014 ... Medical Billing Experts, LLC (MBX) with the convergence ... Medical Professionals (BOSS), Salt Lake City, UT; Premier ... Six Seven Group (67G) of Charlotte, NC. Together ... some of the nation’s largest radiology group practices, ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 According to the ... is a comprehensive diet guide for women who want to ... list of protein rich foods and fat loss ... muscle mass. , Vkool writes in its review that this ... the truth about fat burning hormones and weight loss supplements. ...
(Date:8/1/2014)... The Journal of Neurosurgery is pleased ... the August issue entitled "Race Against the Clock: ... Hemorrhage." Authored by Peter Le Roux, MD, Charles ... and Alisa Schaefer, PhD, the 20-page supplement covers ... and methods in use for management of the ...
(Date:8/1/2014)... Millions of women suffer with lipedema, a ... some cases the arms, causing an abnormal accumulation of ... women in the U.S. alone are affected. With such ... embarrassment and discomfort caused by lipedema, it’s remarkable that ... that this is a disease,” says Dr. David Greuner, surgical ...
(Date:8/1/2014)... 2014 Register to join the webinar here: ... active years on record for life sciences investing. IPOs in ... 22 percent of all venture dollars spent in 2013. The ... valuations. , However, 2014 is proving more of a ... Silicon Valley Bank, while life sciences IPOs are losing steam, ...
Breaking Medicine News(10 mins):Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 2Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 3Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 3Health News:Management of anticoagulant-associated intracerebral hemorrhage 2Health News:Management of anticoagulant-associated intracerebral hemorrhage 3Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3
... Dr. ... , and is giving patients in Texas new reasons to smile. , ... (Vocus) August 24, 2009 -- Mark Sweeney, DDS knows cosmetic dentistry… ... is director of Austin Dental Spa , a practice devoted to turning visits to the ...
... , SEATTLE, Aug. 24 Cell Therapeutics, Inc. ... and Drug Administration (FDA) has accepted and has filed for review ... relapsed or refractory aggressive non-Hodgkin,s lymphoma (NHL). A Prescription Drug User ... the review of the pixantrone NDA by September 4th 2009. ...
... Mortality remains high among patients with pulmonary arterial hypertension ... that were designed to reduce mortality and increase the ... out of University of California San Francisco. ... of the American Journal of Respiratory and Critical ...
... of Idiopathic Pulmonary Fibrosis is not much better than ... survival rate is less than three years. But ... targeting of a novel gene utilizing genetic and pharmacologic ... and will be developed for future testing in humans. ...
... ... Washington D.C. is business owner John Wahlquist of eMedicalSystems, Bremerton, Washington state. Author of his ... choice to retire his product and migrate his medical practices over to a new generation ... ...
... FAYETTE COUNTY, Ga. , Aug. 22 Dominique Wilkins, NBA ... create awareness of the fact that seniors at risk for diabetes ... provider,s office. This is the core message of the Medicare ... in Georgia since 2007 and is co-chaired nationally by the American ...
Cached Medicine News:Health News:Austin Texas Cosmetic Dentist Celebrates 30 Years in Practice 2Health News:Austin Texas Cosmetic Dentist Celebrates 30 Years in Practice 3Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 2Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 3Health News:Still holding their breath: Mortality on lung transplant wait list remains high for some 2Health News:Still holding their breath: Mortality on lung transplant wait list remains high for some 3Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 3Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 2Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 3Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 4
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....
... hinged knee brace provides maximum ... types of sports and activities. ... rubber pads to support medial ... buttress and hyperextension stop. 3/16" ...
Medicine Products: